Inclusion Criteria:

• Healthy, as determined by medical history and physical examination.
• Aged 4 to < 7 years at the time of study vaccination on Day 0.
• Informed consent form that has been approved by the Institutional Review Board (IRB) and signed/dated by the parent or legal guardian.
• Previous documented vaccination history of 4th dose diphtheria, tetanus and acellular pertussis (DTaP) series.

Exclusion Criteria:

• Serious chronic disease (e.g. cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, hematologic)
• Known or suspected impairment of immunologic function
• Acute medical illness with or without fever within the last 72 hours or temperature >= 100.4°F (>= 38°C) at the time of enrollment
• History of documented invasive meningococcal disease or previous meningococcal vaccination
• Received a 5th dose vaccination with any tetanus, diphtheria or pertussis vaccine, or 4th dose of IPV prior to this study.
• Received either immune globulin or other blood products within the last 3 months; or received injected or oral corticosteroids, or other immunomodulator therapy, within 6 weeks of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting <7 days and individuals (e.g., asthmatics) on a short schedule of oral steroids lasting 3 to 4 days may be included in the trial as long as they have not received more than one course within the last 2 weeks prior to enrollment.
• Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw.
• Suspected or known hypersensitivity to any of the study vaccine components, history of serious or life-threatening reaction to the trial vaccines or a vaccine containing the same substances.
• Thrombocytopenia or a bleeding disorder contraindicating IM vaccination.
• Unavailable for the entire study period, or unable to attend the scheduled visits or to comply with the study procedures.
• Enrolled in another clinical trial.
• Diagnosed with any condition, which, in the opinion of the physician investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.
• Received any other vaccine 30 days prior to the first study vaccination or scheduled to receive any vaccination during the course of the study.
• Personal or family history of Guillain-Barré Syndrome (GBS).